Published: 23 December 2021
Author(s): Collaborative group: MI study group
Issue: April 2022
Section: Letter to the Editor

There is an unmet medical need to provide novel treatments with high efficiency and low side effects in patients with sarcoidosis resistant to glucocorticoids or second-line therapies (methotrexate, TNFα inhibitors), or who cannot tolerate them [1].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.